Mirandola (Modena), 12 June 2024 – La ex Bellcoone of the most important companies in the Modena biomedical district, wants to close the production part of the Mirandola plant, retaining only the research and development. There are 350 employees at risk: 300 direct and the rest temporary. Bellco employs over 500 people in Mirandola. We learn this from institutional sources.
Silence from the unions, gathered in an assembly with the workers, after having been informed by company management of the intention to open an anti-delocalization procedure. An intervention by the CEO of Mozarc Medical (the current name of Bellco) is expected, Ven Manda via video conference today.
Shock for one of the most prosperous sectors in the region
For the Mirandola biomedical sector it is a shock. There has never been a corporate crisis like this before. The sector, for decades one of the most prosperous in the region, had been hit hard by the earthquake of 2012 which had its epicenter in this territory. Then the sector restarted, but in recent years suffered from competition foreign, in particular Chinesewhich reduced the margins obtainable on dialysis products.
Among the professionals, there is concern about a situation possible domino effect on other companies in the sector: in particular there are two with the loudest creaks. With the anti-relocation procedure, explain sources close to the dossier, Mozarc Medical aims to find a possible buyer to take over the Mirandola plant. If this is not the case, the collective dismissal procedure will be triggered.
